Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 10:07Maha Othman: Look Forward to an Amazing ISTH 2027 in Vancouver!
-
Oct 10, 2026, 10:02Rucha Patil: National Convening Highlights Opportunities for Equitable Hemophilia Care Across India
-
Oct 10, 2026, 09:52Yuria Ito: Should Ferritin Testing Become a Routine Part of Prenatal Care in Japan?
-
Oct 10, 2026, 09:48Ahmed Alotaibi: Can We “Remove” the ABO Problem from Group O Platelets?
-
Oct 10, 2026, 09:31Help Shape the New ASH Iron Deficiency Guidelines – American Society of Hematology
-
Oct 10, 2026, 09:05Wolfgang Miesbach: Moving from Bleed Control to Comprehensive Joint Health
-
Oct 10, 2026, 07:59Leila Caroline Souza Reis: Enoxaparin Dosing for VTE Prevention in Adults With Obesity
-
Oct 10, 2026, 07:41Adeeb Bazuhair: New Evidence for Catheter Directed Thrombolysis in Acute PE
-
Oct 10, 2026, 07:22Poppy Clarke: Turning Steps Into Support for Thrombosis Awareness